Klinische Studie – Psoriasis und Psoriatische Arthritis (Clinical Trial – Germany)

Zur Studie

with superior selectivity and specificity

Therapeutic peptides

toxins of venomous animals

Derived from evolutionary tuned

which selectively

Peptide drugs

target ion channels

for autoimmune patients

Improving quality of life

Targeting Ion Channels

MORE

si-544 – A Highly Differentiated Asset in Autoimmunity

Best-in-class Kv1.3 blocker
Benchmark for safety and tolerability in autoimmune therapy
Maintains patient’s full immunocompetence
Short treatment course delivers sustained clinical benefit
Pipeline drug for autoimmunity

Our Goal

To improve quality of life for patients by developing best-in-class ion channel blockers.

A highly efficient screening and development platform to identify and optimize the most targeted peptides for our drug development.

Events

Meet selectION, Inc. at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on January 13^th-16^th, 2025

December 11, 2024

SAN DIEGO, Dec 9, 2024 – Meet selectION’s management team for an update on selectION’s best-in-class Kv1.3 ion channel blocker for the treatment of T-cell mediated autoimmunity while maintaining the patients’ full immunocompetence. selectION successfully completed its first-in-human study with…

selectION Announces Initiation of Phase 1b Clinical Trial Evaluating si-544 in Patients with Psoriasis Vulgaris or Psoriatic Arthritis

May 28, 2024

New study follows completion of first-in-human Phase 1b trial in atopic dermatitis patients, in which selectION observed safety and tolerability of si-544 in the treatment of T cell autoimmunity Recruitment is underway, with topline results expected in 4Q24 – San…

Klinische Studie – Psoriasis und Psoriatische Arthritis (Clinical Trial – Germany)

with superior selectivity and specificity

Therapeutic peptides

si-544 – A Highly Differentiated Asset in Autoimmunity

Best-in-class Kv1.3 blocker

Benchmark for safety and tolerability in autoimmune therapy

Maintains patient’s full immunocompetence

Short treatment course delivers sustained clinical benefit

Pipeline drug for autoimmunity

Our Goal

To improve quality of life for patients by developing best-in-class ion channel blockers.

Our Technology

A highly efficient screening and development platform to identify and optimize the most targeted peptides for our drug development.

News & Events

Meet selectION, Inc. at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on January 13^th-16^th, 2025

selectION Announces Initiation of Phase 1b Clinical Trial Evaluating si-544 in Patients with Psoriasis Vulgaris or Psoriatic Arthritis

About

Recent News

Contact

Klinische Studie – Psoriasis und Psoriatische Arthritis (Clinical Trial – Germany)

with superior selectivity and specificity

Therapeutic peptides

si-544 – A Highly Differentiated Asset in Autoimmunity

Best-in-class Kv1.3 blocker

Benchmark for safety and tolerability in autoimmune therapy

Maintains patient’s full immunocompetence

Short treatment course delivers sustained clinical benefit

Pipeline drug for autoimmunity

Our Goal

To improve quality of life for patients by developing best-in-class ion channel blockers.

Our Technology

A highly efficient screening and development platform to identify and optimize the most targeted peptides for our drug development.

News & Events

Meet selectION, Inc. at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on January 13th-16th, 2025

selectION Announces Initiation of Phase 1b Clinical Trial Evaluating si-544 in Patients with Psoriasis Vulgaris or Psoriatic Arthritis

About

Recent News

Contact

Meet selectION, Inc. at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on January 13^th-16^th, 2025